- Home
- CNTX vs COCH Comparison
CNTX vs COCH Comparison
Compare CNTX & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNTX | COCH |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.5M | 53.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNTX | COCH |
|---|---|---|
| Price | $0.62 | $0.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $6.60 | $6.00 |
| AVG Volume (30 Days) | ★ 4.4M | 783.4K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.36 |
| 52 Week High | $3.62 | $1.89 |
Technical Indicators
Market Signals| Indicator | CNTX | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 30.62 | 44.78 |
| Support Level | $0.55 | $0.64 |
| Resistance Level | $0.70 | $0.74 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 40.14 | 10.19 |
Price Performance
Historical ComparisonAbout CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.